The text starts here.

News Release

July 12, 2006
For Print (PDF 73KB)

Eisai and Teva Mutually Agree To End Collaboration Agreement for Rasagiline

Eisai Co., Ltd.
Eisai Inc.

Eisai Co., Ltd. (Headquarters: Tokyo, President and CEO: Haruo Naito) and Eisai Inc. (Headquarters: New Jersey, U.S.A., Chairman and CEO: Hajime Shimizu) jointly announce today that on July 12th, 2006, the companies and Teva Pharmaceutical Industries Ltd. (Headquarters: Jerusalem, Israel, President: Israel Makov) agree to end a collaboration agreement for rasagiline, which was established in May 2003.

Corporate Communications Department
Eisai Co., Ltd.
TEL: +81-3-3817-5120
Cathy Pollini
Corporate Planning and Communications
Eisai Inc.
TEL: +1-201-287-2052